Cantor Fitzgerald analyst Jordan Abrams points out that the deadline for the U.K.'s Competition and Markets Authority to determine whether or not to move to a Phase 2 investigation on Illumina's (ILMN) proposed buyout of Pacific Biosciences (PACB) is June 18. The analyst's due diligence suggests the acquisition is at risk to move to a Phase 2 investigation, but his view is that the deal will ultimately close. Nonetheless, he expects additional pressure on Pacific Biosciences shares if CMA moves forward with a Phase 2 investigation. Pacific shares last closed at a 19% discount $8 acquisition price, and the deal is still expected to close mid-2019, Abrams tells investors in a research note. He keeps a Neutral rating on Pacific Biosciences.